Fig. 5: Schematic diagrams for the TDB + loncastuximab tesirine combination therapy model. | npj Systems Biology and Applications

Fig. 5: Schematic diagrams for the TDB + loncastuximab tesirine combination therapy model.

From: QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy

Fig. 5

A compartmental PK diagram. The PK model includes three compartments: a central compartment (i.e., peripheral blood), a peripheral tissue compartment to account for drug distribution, and a deposit compartment to account for subcutaneous injection. B Tumor B-cell and T-cell dynamics in the presence of TDB and loncastuximab tesirine. T cells in the tumor cycle through resting state, activated state, and postactivated state (exhausted state), and may die at any state. Only activated T cells proliferate and induce both healthy and cancerous B-cell death. All T cells could enter or leave the tumor from/the bloodstream. Loncastuximab tesirine could also induce the death of tumor B cells. Tumor cells killed by loncastuximab tesirine transition to a dying stage before being removed from the tumor. Lonca loncastuximab tesirine, PK pharmacokinetic, TDB T-cell-dependent bispecific antibody. Created in BioRender. Li, Y. (2025) https://BioRender.com/nmbj785.

Back to article page